DICE — Dice Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
Brief: Dice Therapeutics Q1 Loss Per Share USD 0.54
Big pharma interest in immunology sector to grow in near to medium term - Jefferies
DICE Therapeutics rises as Needham starts coverage with 'buy' rating
Needham initiates coverage on DICE Therapeutics with 'buy' rating
Brief: Dice Therapeutics Inc Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing
Brief: Dice Therapeutics Reports Q4 And Full Year 2022 Financial Results And Recent Highlights
Brief: Dice Therapeutics Q4 loss per share of 51 cents
Brief: Dice Therapeutics Reports Third Quarter 2022 Financial Results
Brief: Dice Therapeutics Announces Closing Of Upsized Public Offering
U.S. RESEARCH ROUNDUP-Adobe, BlackRock, Domino's Pizza
U.S. STOCKS ON THE MOVE-Under Armour, VectivBio, Morgan Stanley
U.S. STOCKS ON THE MOVE-Domino's Pizza, Biogen, Twitter
U.S. STOCKS ON THE MOVE-Pfizer, Delta, Relmada Therapeutics
Dice Therapeutics slips after pricing upsized $300 mln stock deal
Brief: Dice Announces Pricing Of Upsized Public Offering Of Common Stock
U.S. RESEARCH ROUNDUP- Boeing, Cooper Companies, Northern Trust
Dice Therapeutics rolls out equity offering after shares soar
Brief: Dice Announces Proposed Public Offering Of Common Stock
Ventyx falls as rival DICE reports positive psoriasis treatment data